{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Updates and Approvals: 2019 in Review
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To highlight specific and comprehensive information about eight new drugs the US Food and Drug Administration approved in 2019.Learning Objectives
After completing this continuing education activity you will be able to:
- Describe the actions of and the indications and contraindications for these eight newly approved drugs.
- List the common adverse reactions of these eight newly approved drugs.
- Plan the appropriate instructions for patients who are prescribed these eight newly approved drugs.
Disclosures
The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
Price:
$17.95
Credits:
- ANCC 1.5 CH / 1.5 APH
- DC - BON 1.5 CH
- KY-BON 1.5 CH
- GA - BON 1.5 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
Awarded Advanced Pharmacology Hours
Awarded Advanced Pharmacology Hours
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: NP1219A
Published: Dec 2019
Expires: 12/31/2026
Required Passing Score: 13/18 (72%)
Specialties:
Primary Care
Topics:
Drug Update